Skip to main content
SpringerLink
Log in

Pharmacochemical aspects of leprosy

Recent developments and prospects for new drugs

  • Update Articles
  • Published:
Pharmaceutisch Weekblad Aims and scope Submit manuscript

Abstract

From a pharmacochemical point of view the existing anti-leprotics as well as possible innovations in the chemotherapy of leprosy are discussed. Of the main anti-leprotics, which are used nowadays — dapsone, rifampicin, clofazimine, isoniazide, ethionamide and prothionamide — the mechanism of action, the main problems in their application and possibilities to develop improved variants are reviewed. Based on the chemistry ofMycobacterium leprae, the target systems for new anti-leprotics are identified. These systems include the cell wall, the catabolism of reactive oxygen species, the metabolisms of carbon sources, the amino acid metabolism and the uptake of iron. Two possible new lead structures from other fields, 4-quinolones and mycobacterial ribonucleotide reductase inhibitors are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anonymous. Vaccination trials against leprosy. A meeting of the epidemiology subgroup of the scientific working group on the immunology of leprosy. WHO/TDR/IMMLEP/EPD/85.3, 1985.

  2. Seydel JK, Wempe EG. Bacterial growth kinetics ofM. lufu, in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy againstM. leprae. Int J Lepr 1982;50(1):20–31.

    Google Scholar 

  3. Acocella G. Rifampicin: a brief outline of its microbiological, pharmacokinetic and clinical features. Quad Cooperazione Sanitaria 1981;1:21–3.

    Google Scholar 

  4. Leiker DL. Clofazimine in the treatment of leprosy. Quad Cooperazione Sanitaria 1982;1:155–8.

    Google Scholar 

  5. Shepard CC, Van Landingham RM, Walker LL. Recent studies of antileprosy drugs. Lepr Rev 1983;54:235–305.

    Google Scholar 

  6. Cabot MC. Chaulmoogric acid. Assimilation into the complex lipids of mycobacteria. Lipids 1981;16(2):146–8.

    PubMed  Google Scholar 

  7. Chaudhuri S, Glosh S, Chakraborty T, Kundu S, Hazra SK. Use of a common Indian herb Mandukarpani in the treatment of leprosy. Lepr India 1979;51(1):106–11.

    PubMed  Google Scholar 

  8. Kulkarni VM, Seydel JK. Inhibitory activity and mode of action of DDS in cell free folate synthesizing system fromM. lufu andM. leprae. Chemotherapy 1983;29:58–67.

    PubMed  Google Scholar 

  9. Seydel JK, Wempe EG, Rosenfeld M. Bacterial growth kinetics ofE. coli and mycobacteria in the presence of bromoprim and metioprim alone and in combination with aulfamemazine and dapsone. IV. Chemotherapy 1983;29:249–62.

    PubMed  Google Scholar 

  10. Ungheri D, Bruna DC, Sanfilipo A. Studies on the mechanism of action of the spiropiperidyl rifampicin LM.427 on rifampicin-resistantM. tuberculosis. Drugs Exp Clin Res 1984;10:681–9.

    Google Scholar 

  11. Arioli V, Berti M, Garniti G. Antibacterial activity of DL.473, a new semi-synthetic rifamycin derivative. J Antiobiot (Tokyo) 1981;34(8):1026–32.

    Google Scholar 

  12. Zierksi M, Rotermund C. Isoniazid: essential facts and new information. Prax Klin Pneumol 1984;38:65–73.

    Google Scholar 

  13. Draper P. Wall biosynthesis: a possible site of action for new anti-mycobacterial drugs. Int J Lepr 1984;52(4):527–32.

    Google Scholar 

  14. Wheeler PR. Metabolism inM. leprae. Its relation to other research onM. leprae and to aspects of metabolism in other mycobacteria and intracellular parasites [Editorial]. Int J Lepr 1984;52(2):208–30.

    Google Scholar 

  15. Jayamaran P, Mahadevan P, Mester L, Mester M. Inhibition of the incorporation of3H-DOPA inM. leprae by DFS. Biochem Pharm 1980;29:2526–8.

    Article  PubMed  Google Scholar 

  16. Ferraci C, Baquillon G, Pattyn SR. Action of DFS onM. leprae. Results of inoculation of mice with human biopsies taken after 1 year of treatment. Acta Leprol 1983;93:233–5.

    Google Scholar 

  17. Mester L, Rees RJW, Ambrose ES, Mester M. A series of new anti-leprosy compounds derived from serotonin. Acta Leprol Logica 1985:21–8.

  18. Kato L. Absence of micobactin inM. leprae. Probably a microbe-dependent micro-organism: implications. Indian J Lepr 1985;57(1):58–70.

    PubMed  Google Scholar 

  19. Guelpa-Lanras C, Perani EG, Giroir A, Grosset JH. Activitities of pefloxacin and ciprofloxacin againstM. leprae in the mouse. Int J Lepr 1987;55(1):70–7.

    Google Scholar 

  20. Saito H, Tomioka H, Nagashima K.In vitro andin vivo activities of ofloxacin againstM. leprae infection induced in mouse. Int J Lepr 1986;54(4):560–2.

    Google Scholar 

  21. Schaper K-J, Seydel JK, Rosenfeld M, Kazda J. Development of inhibitors of mycobacterial ribonucleotide reductase. Lepr Rev 1986;57:254–64.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacochemistry, Free University, De Boelelaan 1083, 1081, HV Amsterdam, The Netherlands

    P. van Saane &  H. Timmerman

Authors
  1. P. van Saane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Timmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Saane, P., Timmerman, H. Pharmacochemical aspects of leprosy. Pharmaceutisch Weekblad Scientific Edition 11, 3–8 (1989). https://doi.org/10.1007/BF01972907

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01972907

Keywords

Search

Navigation